Volume 2 - Issue 1, January - February 2026

Diabetes mellitus (DM) is characterized by an absolute decline in insulin secretion and peripheral resistance and is the most prevalent metabolic and endocrine disorder. However, the pathogenesis of DM also includes adipocyte insulin resistance, increased glucagon secretion, increased renal glomerular glucose absorption, and neurotransmitter dysfunction Current therapeutic interventions against DM focus mostly on glycaemic control without considering the other pathological determinants that eventually lead to treatment failure and the progression of DM. Diabetes Mellitus (DM) is a multi-factorial chronic health condition that affects a large part of population and according to the World Health Organization (WHO) the number of adults living with diabetes is expected to increase. Since type 2 diabetes mellitus (T2DM) is suffered by the majority of diabetic patients (around 90–95%) and often the mono-target therapy fails in managing blood glucose levels and the other comorbidities, this review focuses on the potential drugs acting on multi-targets involved in the treatment of this type of diabetes. In particular, the review considers the main systems directly involved in T2DM or involved in diabetes comorbidities. Agonists acting on incretin, glucagon systems, as well as on peroxisome proliferation activated receptors are considered. Inhibitors which target either aldose reductase and tyrosin phosphatase 1B or sodium glucose transporters 1 and 2 are taken into account.

M.Shammi, Dr.D.Rama Brahma Reddy, Dr.Ch.N.V.S Mastan Rao,"Noval Targets for Diabetes Management Drug Information Services" International Journal of Scientific Research and Engineering Development, V2(1): Page(492-500) Jan-Feb 2026. ISSN: 3107-6513. www.ijamred.com. Published by Scientific and Academic Research Publishing.